MOSEGOR 0.5/MG TAB 30/TAB

Indications

Approved Uses

Prophylaxis of recurrent vascular headaches, including migraine (classical/common) and cluster headache.

Side Effects

Common Side Effects

Increased appetite, weight gain, drowsiness, sedation, fatigue, dizziness, nausea, dry mouth.

Safety & Warnings

Driving Warning

May Cause Drowsiness

Storage & Patient Advice

Overdose

Symptoms: marked drowsiness/sedation, dizziness, nausea/vomiting, anticholinergic features (dry mouth, mydriasis, tachycardia, urinary retention), hypotension; seizures/convulsions (especially in children) and coma can occur. Management: urgent medical care, activated charcoal if appropriate, supportive/symptomatic treatment; consider specific management for severe anticholinergic toxicity per toxicology guidance.

Patient Counseling

Used for migraine prevention (not for treating an acute attack); take daily as directed and expect benefit after several weeks (often 2-4 weeks). Drowsiness is common-prefer taking the larger dose at bedtime and avoid driving/operating machinery until effects are known; avoid alcohol. Increased appetite/weight gain can occur-monitor weight and diet. Do not stop abruptly without clinician advice; seek advice if troublesome sedation, significant weight gain, urinary retention, or worsening symptoms occur.

Pharmacology

Mechanism of Action

Primarily a serotonin 5‑HT2 receptor antagonist with additional histamine H1 antagonism (and mild anticholinergic effects), reducing serotonergic/amine-mediated vascular and neurogenic mechanisms implicated in migraine prophylaxis.

Half-Life

Approximately 23 hours.

Bioavailability

Approximately 78-80%.

Metabolism

Extensively metabolized hepatically, primarily by N-glucuronidation (forming an N-glucuronide metabolite).

Protein Binding

Approximately 91%.

Product Information

Primary Use

For the prevention of migraine and other vascular headaches.

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 28-07-2026